Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater ...

Latham leaders said they had their eyes on recruiting David Marriott for “several years,” particularly after working ...

In an en banc petition filed this month before the U.S. Court of Appeals for the Ninth Circuit, Takeda Pharmaceutical and Eli ...

In letters posted on Truth Social, Trump demanded that drugmakers offer their medications at the same prices paid abroad.

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.

New research results reported at the Alzheimer's Association International Conference® 2025 (AAIC®) advanced scientific understanding of ...

On a tumultuous trading day, Eli Lilly and Co. (LLY) showcased a dramatic stock performance that belied its closing uptick. Starting the day with high hopes, the stock surged to a peak before plunging ...

COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk on Tuesday cut its full-year sales and operating profit forecasts for ...

Investors are awaiting the Federal Reserve's interest rate announcement Wednesday afternoon. Fed funds futures are pricing in ...

One of the more popular stocks in the pharmaceutical sector of late got the cold shoulder from investors on Tuesday. Eli Lilly (NYSE: LLY) closed today's trading session down by almost 6% in value, ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...